Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371351 | 1.00 | AAK1 (0.39) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL31387525 | 0.85 | AAK1 (0.36) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL8276956 | 0.85 | MEN1 (0.33) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL15413915 | 0.85 | MEN1 (0.33) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL27244779 | 0.84 | AAK1 (0.40) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL27244783 | 0.84 | AAK1 (0.40) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL15251813 | 0.84 | AAK1 (0.37) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL15251804 | 0.84 | AAK1 (0.37) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL15251805 | 0.84 | AAK1 (0.37) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL31484511 | 0.83 | MEN1 (0.33) | MEN1KMT2AGAAHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-8247442-B2 | Benzenesulfonamide compounds and their use | PURDUE PHARMA L.P. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247442-B2 | Benzenesulfonamide compounds and their use | PURDUE PHARMA L.P. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | AAK1 1519/4885CTSL 1186/4885CTSB 1411/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | AAK1 1519/4885CTSL 1186/4885CTSB 1411/4885 |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | CACNA1E, CACNA1A, KCNN3 | AAK1 1714/4885CTSL 1170/4885CTSB 1123/4885 |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | AAK1 3988/4885CTSL 1088/4885CTSB 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.